Wei Wang
Impact in
- Oncology top 0.5%
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Lung Cancer Diagnosis and Treatment 45
- Lung Cancer Treatments and Mutations 33
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 26
- Respiratory Support and Mechanisms 16
- Oncology 86
- Cancer Immunotherapy and Biomarkers 38
- Co-authors
- Jianxing He (60 shared papers)Wenhua Liang (32 shared papers)Hengrui Liang (28 shared papers)Wei‐jie Guan (4 shared papers)Caichen Li (7 shared papers)Jianfu Li (7 shared papers)Ke Xu (5 shared papers)Shiyue Li (4 shared papers)
- Journals
- PLoS ONE (9 papers)Medicine (9 papers)Journal of Clinical Oncology (8 papers)Translational Lung Cancer Research (8 papers)Frontiers in Oncology (7 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Wei Wang
397 papers receiving 10.0k citations
Wei Wang's Hit Papers
Peers
Comparison fields: 5 of 174
- Oncology 3.4k
- Infectious Diseases 1.6k
- Cancer Research 1.2k
- Pulmonary and Respiratory Medicine 2.2k
- Neurology 468
Countries citing papers authored by Wei Wang
This map shows the geographic impact of Wei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Wang more than expected).
Fields of papers citing papers by Wei Wang
This network shows the impact of papers produced by Wei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Wang. The network helps show where Wei Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 447 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Hit paper breakdown → | 2020 | 2890 |
| 2 | Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China Hit paper breakdown → | 2020 | 618 |
| 3 | 2012 | 192 | |
| 4 | 2020 | 178 | |
| 5 | 2010 | 143 | |
| 6 | 2019 | 136 | |
| 7 | 2019 | 119 | |
| 8 | 2014 | 116 | |
| 9 | 2021 | 109 | |
| 10 | 2015 | 103 | |
| 11 | 2018 | 101 | |
| 12 | 2013 | 101 | |
| 13 | 2020 | 85 | |
| 14 | 2016 | 84 | |
| 15 | 2017 | 71 | |
| 16 | 2009 | 71 | |
| 17 | 2019 | 69 | |
| 18 | 2016 | 67 | |
| 19 | 2007 | 65 | |
| 20 | 2022 | 64 |
About Wei Wang
Wei Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery and Cancer Research, having authored 447 papers that have together received 10.1k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (45 papers), Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Treatments and Mutations (33 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (26 papers), MicroRNA in disease regulation (23 papers), Cancer-related molecular mechanisms research (18 papers), Respiratory Support and Mechanisms (16 papers) and Esophageal Cancer Research and Treatment (15 papers). The work is most often cited by research in Oncology (3.4k citations), Infectious Diseases (1.6k citations), Cancer Research (1.2k citations), Pulmonary and Respiratory Medicine (2.2k citations) and Neurology (468 citations). Wei Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jianxing He, Wenhua Liang, Hengrui Liang, Wei‐jie Guan, Caichen Li, Jianfu Li, Ke Xu, Shiyue Li, Ruchong Chen and Qing Ai. Their work appears in journals such as PLoS ONE, Medicine, Journal of Clinical Oncology, Translational Lung Cancer Research and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.